VA
TLX

Vident Advisory’s Telix Pharmaceuticals TLX Stock Holding History

Vident Advisory’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Sell
16,653
-10,596
-39% -$80.7K ﹤0.01% 1750
2025
Q4 		$204K Buy
+27,249
New +$262K ﹤0.01% 1548

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Vident Advisory's TLX Position: Q1 2026 in Review

Vident Advisory reduced its Telix Pharmaceuticals (TLX) stake by 39% in Q1 2026, selling an estimated $80.7K and leaving 16,653 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Vident Advisory first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. The position peaked at $204K in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Vident Advisory held 16,653 shares of Telix Pharmaceuticals worth $159K as of Q1 2026.
  • Vident Advisory sold 10,596 Telix Pharmaceuticals shares in Q1 2026, an estimated $80.7K.
  • Telix Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1750 holding.
  • Vident Advisory first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Vident Advisory's Telix Pharmaceuticals position peaked at $204K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.